Genetics of iron regulation and the possible role of iron in Parkinson's disease

Neurobiology of Disease

Volumn 32, Issue 2, 2008, Pages 183-195

  Rhodes, Shannon L ^a   Ritz, Beate ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Iron regulatory proteins; Parkinson's disease; Pathogenesis

Indexed keywords

ALPHA SYNUCLEIN; CERULOPLASMIN; FERRITIN; FRATAXIN; IRON; LACTOFERRIN; PESTICIDE; PROTEASOME; TRANSFERRIN; TRANSFERRIN RECEPTOR; UBIQUITIN;

AGE DISTRIBUTION; CIGARETTE SMOKING; CLINICAL FEATURE; COFFEE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; HUMAN; IRON BALANCE; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LEWY BODY; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; IRON; IRON-REGULATORY PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 53749096620     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.07.001     Document Type: Review

References (203)

1. Aamodt A., Stovner L., Thorstensen K., Lydersen S., White L., and Aasly J. Prevalence of haemochromatosis gene mutations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 315-317
2. Aime S., Bergamasco B., Biglino D., Digilio G., Fasano M., Giamello E., and Lopiano L. EPR investigations of the iron domain in neuromelanin. Biochim. Biophys. Acta 1361 (1997) 49-58
3. Akbas N., Hochstrasser H., Deplazes J., Tomiuk J., Bauer P., Walter U., Behnke S., Riess O., and Berg D. Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 407 (2006) 16-19
4. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 Suppl (2004) S18-S25
5. Anderson C., Checkoway H., Franklin G.M., Beresford S., Smith-Weller T., and Swanson P.D. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord. 14 (1999) 21-27
6. Aoki S., Okada Y., Nishimura K., Barkovich A.J., Kjos B.O., Brasch R.C., and Norman D. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 172 (1989) 381-385
7. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., and Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 274 (1999) 1116-1123
8. Azam S., Hadi N., Khan N.U., and Hadi S.M. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med. Sci. Monit. 9 (2003) BR325-BR330
9. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., Campagna J.A., Chung R.T., Schneyer A.L., Woolf C.J., Andrews N.C., and Lin H.Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38 (2006) 531-539
10. Bagade, S., Allen, N.C., Tanzi, R., Bertram, L., 2006. The PDGene Database. Alzheimer Research Forum. Last updated 2006. Available at: http://www.pdgene.org/. Accessed Oct 28, 2007.
11. Ben-Shachar D., Pinhassi B., and Youdim M.B. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment. Eur. J. Pharmacol. 202 (1991) 177-183
12. Ben-Shachar D., and Youdim M.B. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57 (1991) 2133-2135
13. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., and Rocca W.A. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 16 (2001) 830-837
14. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. Neurochem. Res. 32 (2007) 1646-1654
15. Berg D., Siefker C., and Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248 (2001) 684-689
16. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 Suppl 1 (2005) S17-S27
17. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., Brice A., Durr A., and Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249 (2002) 801-804
18. Braak H., Sandmann-Keil D., Gai W., and Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci. Lett. 265 (1999) 67-69
19. Bridge M.H., Williams E., Lyons M.E., Tipton K.F., and Linert W. Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. Biochim. Biophys. Acta 1690 (2004) 77-84
20. Bridle K.R., Frazer D.M., Wilkins S.J., Dixon J.L., Purdie D.M., Crawford D.H., Subramaniam V.N., Powell L.W., Anderson G.J., and Ramm G.A. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 361 (2003) 669-673
21. Buchanan D.D., Silburn P.A., Chalk J.B., Le Couteur D.G., and Mellick G.D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 327 (2002) 91-94
22. Burdo J.R., Menzies S.L., Simpson I.A., Garrick L.M., Garrick M.D., Dolan K.G., Haile D.J., Beard J.L., and Connor J.R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66 (2001) 1198-1207
23. Burn J., and Chinnery P.F. Neuroferritinopathy. Semin. Pediatr. Neurol. 13 (2006) 176-181
24. Casiday, R., Frey, R., 2000. Iron in biology: study of the iron content in ferritin, the iron-storage protein. Last updated 2000. http://www.chemistry.wustl.edu/~edudev/LabTutorials/ Ferritin/Ferritin.html. Accessed Jan 29, 2007.
25. Chen R., Langston J.W., and Chan P. Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America. Neurosci. Lett. 335 (2002) 144-146
26. Chen T.T., Li L., Chung D.H., Allen C.D., Torti S.V., Torti F.M., Cyster J.G., Chen C.Y., Brodsky F.M., Niemi E.C., Nakamura M.C., Seaman W.E., and Daws M.R. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J. Exp. Med. 202 (2005) 955-965
27. Chinnery P.F., Curtis A.R.J., Fey C., Coulthard A., Crompton D., Curtis A., Lombes A., and Burn J. Neuroferritinopathy in a French family with late onset dominant dystonia. J. Med. Genet. 40 (2003) e69
28. Chun H.S., Gibson G.E., DeGiorgio L.A., Zhang H., Kidd V.J., and Son J.H. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76 (2001) 1010-1021
29. Collins J.F., Franck C.A., Kowdley K.V., and Ghishan F.K. Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G964-G971
30. Connor J.R. Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction. Dev. Neurosci. 16 (1994) 233-247
31. Connor J.R., and Menzies S.L. Relationship of iron to oligodendrocytes and myelination. Glia. 17 (1996) 83-93
32. Connor J.R., Menzies S.L., St Martin S.M., and Mufson E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27 (1990) 595-611
33. Curtis A.R.J., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28 (2001) 350-354
34. Daglia M., Papetti A., Gregotti C., Berte F., and Gazzani G. In vitro antioxidant and ex vivo protective activities of green and roasted coffee. J. Agric. Food Chem. 48 (2000) 1449-1454
35. Daglia M., Racchi M., Papetti A., Lanni C., Govoni S., and Gazzani G. In vitro and ex vivo antihydroxyl radical activity of green and roasted coffee. J. Agric. Food Chem. 52 (2004) 1700-1704
36. Dandekar T., Stripecke R., Gray N.K., Goossen B., Constable A., Johansson H.E., and Hentze M.W. Identification of a novel iron-responsive element in murine and human erythroid delta-aminolevulinic acid synthase mRNA. EMBO J. 10 (1991) 1903-1909
37. Davies K.J. Protein damage and degradation by oxygen radicals. I. general aspects. J. Biol. Chem. 262 (1987) 9895-9901
38. de Lau L.M., and Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 5 (2006) 525-535
39. Dekker M.C., Giesbergen P.C., Njajou O.T., van Swieten J.C., Hofman A., Breteler M.M., and van Duijn C.M. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci. Lett. 348 (2003) 117-119
40. Demeule M., Poirier J., Jodoin J., Bertrand Y., Desrosiers R.R., Dagenais C., Nguyen T., Lanthier J., Gabathuler R., Kennard M., Jefferies W.A., Karkan D., Tsai S., Fenart L., Cecchelli R., and Beliveau R. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83 (2002) 924-933
41. Deplazes J., Schobel K., Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Becker G., Riess O., and Berg D. Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. J. Neural Transm. 111 (2004) 515-521
42. Descamps L., Dehouck M.P., Torpier G., and Cecchelli R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. 270 (1996) H1149-H1158
43. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., and Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987) 1219-1220
44. Dick F.D., De Palma G., Ahmadi A., Osborne A., Scott N.W., Prescott G.J., Bennett J., Semple S., Dick S., Mozzoni P., Haites N., Wettinger S.B., Mutti A., Otelea M., Seaton A., Soderkvist P., and Felice A. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Environ. Med. 64 (2007) 673-680
45. Double K.L., Ben-Shachar D., Youdim M.B., Zecca L., Riederer P., and Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24 (2002) 621-628
46. Double K.L., Gerlach M., Schunemann V., Trautwein A.X., Zecca L., Gallorini M., Youdim M.B., Riederer P., and Ben-Shachar D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66 (2003) 489-494
47. Double K.L., Gerlach M., Youdim M.B., and Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural Transm., Suppl. (2000) 37-58
48. Elbaz A., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., and Rocca W.A. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55 (2002) 25-31
49. Elbirt K.K., and Bonkovsky H.L. Heme oxygenase: recent advances in understanding its regulation and role. Proc. Assoc. Am. Physicians 111 (1999) 438-447
50. Ezquerra M., Campdelacreu J., Munoz E., and Tolosa E. Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. J. Neurol. 252 (2005) 1269-1270
51. Fasano M., Giraudo S., Coha S., Bergamasco B., and Lopiano L. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. Neurochem. Int. 42 (2003) 603-606
52. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., and Double K.L. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 75 (2005) 109-124
53. Felletschin B., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Sommer U., Zeiler B., Becker G., Riess O., and Berg D. Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 352 (2003) 53-56
54. Fillebeen C., Descamps L., Dehouck M.P., Fenart L., Benaissa M., Spik G., Cecchelli R., and Pierce A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274 (1999) 7011-7017
55. Fisher J., Devraj K., Ingram J., Slagle-Webb B., Madhankumar A.B., Liu X., Klinger M., Simpson I.A., and Connor J.R. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am. J. Physiol. Cell Physiol. 293 (2007) C641-C649
56. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., and Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18 (1987) 299-304
57. Foglieni B., Ferrari F., Goldwurm S., Santambrogio P., Castiglioni E., Sessa M., Volonte M.A., Lalli S., Galli C., Wang X.S., Connor J., Sironi F., Canesi M., Biasiotto G., Pezzoli G., Levi S., Ferrari M., Arosio P., and Cremonesi L. Analysis of ferritin genes in Parkinson disease. Clin. Chem. Lab. Med. 45 (2007) 1450-1456
58. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
59. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., and Archer T. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol. Appl. Pharmacol. 159 (1999) 25-30
60. Fredriksson A., Schroder N., Eriksson P., Izquierdo I., and Archer T. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism. Relat. Disord. 7 (2001) 97-105
61. Friedlich A.L., Tanzi R.E., and Rogers J.T. The 5¢-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 12 (2007) 222-223
62. Gaeta A., and Hider R.C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146 (2005) 1041-1059
63. Ganz T. Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract. Res., Clin. Haematol. 18 (2005) 171-182
64. Gerlach M., Ben-Shachar D., Riederer P., and Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J. Neurochem. 63 (1994) 793-807
65. Glinka Y., Tipton K.F., and Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 66 (1996) 2004-2010
66. Golts N., Snyder H., Frasier M., Theisler C., Choi P., and Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277 (2002) 16116-16123
67. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., and Richardson R.J. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48 (1997) 650-658
68. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., and Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45 (1995) 1138-1143
69. Gorell J.M., Peterson E.L., Rybicki B.A., and Johnson C.C. Multiple risk factors for Parkinson's disease. J. Neurol. Sci. 217 (2004) 169-174
70. Gotz M.E., Double K., Gerlach M., Youdim M.B., and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012 (2004) 193-208
71. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
72. Griffiths T.A., Mauk A.G., and MacGillivray R.T. Recombinant expression and functional characterization of human hephaestin: a multicopper oxidase with ferroxidase activity. Biochemistry 44 (2005) 14725-14731
73. Guerreiro R.J., Bras J.M., Santana I., Januario C., Santiago B., Morgadinho A.S., Ribeiro M.H., Hardy J., Singleton A., and Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 6 (2006) 24
74. Gunshin H., Allerson C.R., Polycarpou-Schwarz M., Rofts A., Rogers J.T., Kishi F., Hentze M.W., Rouault T.A., Andrews N.C., and Hediger M.A. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett. 509 (2001) 309-316
75. Gunshin H., Fujiwara Y., Custodio A.O., Direnzo C., Robine S., and Andrews N.C. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J. Clin. Invest. 115 (2005) 1258-1266
76. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., and Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 (1997) 482-488
77. Hahn P., Qian Y., Dentchev T., Chen L., Beard J., Harris Z.L., and Dunaief J.L. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13850-13855
78. Hallgren B., and Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3 (1958) 41-51
79. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., Booij J., Dluzen D.E., and Horstink M.W. Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 819-824
80. Hentze M.W., Caughman S.W., Rouault T.A., Barriocanal J.G., Dancis A., Harford J.B., and Klausner R.D. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science. 238 (1987) 1570-1573
81. Hentze M.W., Muckenthaler M.U., and Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 117 (2004) 285-297
82. Hernan M.A., Takkouche B., Caamano-Isorna F., and Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52 (2002) 276-284
83. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Zeiler B., Bornemann A., Pahnke J., Becker G., Riess O., and Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63 (2004) 1912-1917
84. Höck A., Demmel U., Schicha H., Kasperek K., and Feinendegen L.E. Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium. Brain 98 (1975) 49-64
85. Hoepken H.H., Korten T., Robinson S.R., and Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 88 (2004) 1194-1202
86. Hurrell R.F., Reddy M., and Cook J.D. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br. J. Nutr. 81 (1999) 289-295
87. Ii K., Ito H., Tanaka K., and Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56 (1997) 125-131
88. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., and Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 312 (1984) 162-163
89. Johnson C.C., Gorell J.M., Rybicki B.A., Sanders K., and Peterson E.L. Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 28 (1999) 1102-1119
90. Johnson M.B., and Enns C.A. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 104 (2004) 4287-4293
91. Kalivendi S.V., Cunningham S., Kotamraju S., Joseph J., Hillard C.J., and Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 279 (2004) 15240-15247
92. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., and Andersen J.K. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging 28 (2007) 907-913
93. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
94. Kawabata H., Fleming R.E., Gui D., Moon S.Y., Saitoh T., O'Kelly J., Umehara Y., Wano Y., Said J.W., and Koeffler H.P. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 105 (2005) 376-381
95. Kawabata H., Germain R.S., Vuong P.T., Nakamaki T., Said J.W., and Koeffler H.P. Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275 (2000) 16618-16625
96. Ke Y., and Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2 (2003) 246-253
97. Knutson M., Menzies S., Connor J., and Wessling-Resnick M. Developmental, regional, and cellular expression of SFT/UbcH5A and DMT1 mRNA in brain. J. Neurosci. Res. 76 (2004) 633-641
98. Koeller D.M., Casey J.L., Hentze M.W., Gerhardt E.M., Chan L.N., Klausner R.D., and Harford J.B. A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 3574-3578
99. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., and Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480 (2000) 147-150
100. Kress G.J., Dineley K.E., and Reynolds I.J. The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. J. Neurosci. 22 (2002) 5848-5855
101. Lai B.C., Marion S.A., Teschke K., and Tsui J.K. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat. Disord. 8 (2002) 297-309
102. Lan J., and Jiang D.H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104 (1997) 649-660
103. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219 (1983) 979-980
104. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer III R., Grinberg A., Love P., Tresser N., and Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet 27 (2001) 209-214
105. Lee P.L., Gelbart T., West C., Halloran C., Sipe J.C., and Beutler E. Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease. Mov. Disord. 17 (2002) 1302-1304
106. Levenson C.W., Cutler R.G., Ladenheim B., Cadet J.L., Hare J., and Mattson M.P. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp. Neurol. 190 (2004) 506-514
107. Lin E., Graziano J.H., and Freyer G.A. Regulation of the 75-kDa subunit of mitochondrial complex I by iron. J. Biol. Chem. 276 (2001) 27685-27692
108. Linert W., Bridge M.H., Huber M., Bjugstad K.B., Grossman S., and Arendash G.W. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim. Biophys. Acta 1454 (1999) 143-152
109. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., and Youdim M.B. Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316 (1996) 160-168
110. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., and LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65 (1995) 710-724
111. Logroscino G., Marder K., Graziano J., Freyer G., Slavkovich V., LoIacono N., Cote L., and Mayeux R. Altered systemic iron metabolism in Parkinson's disease. Neurology 49 (1997) 714-717
112. Lopiano L., Chiesa M., Digilio G., Giraudo S., Bergamasco B., Torre E., and Fasano M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta 1500 (2000) 306-312
113. Lozoff B., Beard J., Connor J., Barbara F., Georgieff M., and Schallert T. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr. Rev. 64 (2006) S34-S43
114. Mack U., Powell L.W., and Halliday J.W. Detection and isolation of a hepatic membrane receptor for ferritin. J. Biol. Chem. 258 (1983) 4672-4675
115. Mancuso C., Scapagini G., Currò D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., and Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12 (2007) 1107-1123
116. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (2002) 1641-1644
117. Martin W.R., Wieler M., and Gee M. Midbrain iron content in early Parkinson disease. A potential biomarker of disease status. Neurology 70 (2008) 1411-1417
118. Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na, H.M., Gutekunst, C.A., Gearing, M., Chu, C.T., Peng, J., Greenamyre, J.T., in press. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease.
119. McCormack A.L., and Di Monte D.A. Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J. Neurochem. 85 (2003) 82-86
120. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., and Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 (2002) 119-127
121. McKie A.T., Barrow D., Latunde-Dada G.O., Rolfs A., Sager G., Mudaly E., Mudaly M., Richardson C., Barlow D., Bomford A., Peters T.J., Raja K.B., Shirali S., Hediger M.A., Farzaneh F., and Simpson R.J. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291 (2001) 1755-1759
122. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5 (2000) 299-309
123. Michaeli S., Oz G., Sorce D.J., Garwood M., Ugurbil K., Majestic S., and Tuite P. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov. Disord. 22 (2007) 334-340
124. Moos T., and Morgan E.H. The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J. Neurochem. 88 (2004) 233-245
125. Moos T., Oates P.S., and Morgan E.H. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J. Comp. Neurol. 398 (1998) 420-430
126. Moos T., Skjoerringe T., Gosk S., and Morgan E.H. Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1. J. Neurochem. 98 (2006) 1946-1958
127. Morck T.A., Lynch S.R., and Cook J.D. Inhibition of food iron absorption by coffee. Am. J. Clin. Nutr. 37 (1983) 416-420
128. Morel I., Lescoat G., Cillard P., and Cillard J. Role of flavonoids and iron chelation in antioxidant action. Methods Enzymol. 234 (1994) 437-443
129. Moroo I., Ujiie M., Walker B.L., Tiong J.W., Vitalis T.Z., Karkan D., Gabathuler R., Moise A.R., and Jefferies W.A. Identification of a novel route of iron transcytosis across the mammalian blood-brain barrier. Microcirculation 10 (2003) 457-462
130. Munch G., Luth H.J., Wong A., Arendt T., Hirsch E., Ravid R., and Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation?. J. Chem. Neuroanat. 20 (2000) 253-257
131. Natella F., Nardini M., Giannetti I., Dattilo C., and Scaccini C. Coffee drinking influences plasma antioxidant capacity in humans. J. Agric. Food Chem. 50 (2002) 6211-6216
132. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
133. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., and Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113 (2004) 1271-1276
134. Nemeth E., Roetto A., Garozzo G., Ganz T., and Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood 105 (2005) 1803-1806
135. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., and Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8780-8785
136. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., Beaumont C., Kahn A., and Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110 (2002) 1037-1044
137. Nicolas G., Bennoun M., Porteu A., Mativet S., Beaumont C., Grandchamp B., Sirito M., Sawadogo M., Kahn A., and Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4596-4601
138. Ohgami R.S., Campagna D.R., Greer E.L., Antiochos B., McDonald A., Chen J., Sharp J.J., Fujiwara Y., Barker J.E., and Fleming M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 37 (2005) 1264-1269
139. Ong W.Y., and Farooqui A.A. Iron, neuroinflammation, and Alzheimer's disease. J. Alzheimers Dis. 8 (2005) 183-200 discussion 209-15
140. Oshiro S., Kawahara M., Kuroda Y., Zhang C., Cai Y., Kitajima S., and Shirao M. Glial cells contribute more to iron and aluminum accumulation but are more resistant to oxidative stress than neuronal cells. Biochim. Biophys. Acta 1502 (2000) 405-414
141. Oshiro S., Kawamura K., Zhang C., Sone T., Morioka M.S., Kobayashi S., and Nakajima K. Microglia and astroglia prevent oxidative stress-induced neuronal cell death: implications for aceruloplasminemia. Biochim. Biophys. Acta 1782 (2008) 109-117
142. Pan W., Kastin A.J., Zankel T.C., van Kerkhof P., Terasaki T., and Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117 (2004) 5071-5078
143. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann. N. Y. Acad. Sci. 1012 (2004) 1-13
144. Peng J., Peng L., Stevenson F.F., Doctrow S.R., and Andersen J.K. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J. Neurosci. 27 (2007) 6914-6922
145. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., and Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276 (2001) 7811-7819
146. Poirier J., Donaldson J., and Barbeau A. The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochem. Biophys. Res. Commun. 128 (1985) 25-33
147. Ponting C.P. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?. Hum. Mol. Genet. 10 (2001) 1853-1858
148. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., Leimpeter A., and Nelson L.M. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 65 (2005) 383-390
149. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., Swanson P.D., and Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60 (2003) 1761-1766
150. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ. Res. 86 (2001) 122-127
151. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
152. Qian Z.M., and Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res. Brain Res. Rev. 27 (1998) 257-267
153. Ragonese P., D'Amelio M., Salemi G., Aridon P., Gammino M., Epifanio A., Morgante L., and Savettieri G. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62 (2004) 2010-2014
154. Ragonese P., D'Amelio M., Callari G., Salemi G., Morgante L., and Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov. Disord. 21 (2006) 2211-2214
155. Ragonese P., D'Amelio M., and Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann. N. Y. Acad. Sci. 1089 (2006) 373-382
156. Regan R.F., Kumar N., Gao F., and Guo Y. Ferritin induction protects cortical astrocytes from heme-mediated oxidative injury. Neuroscience 113 (2002) 985-994
157. Richardson D.R., and Morgan E.H. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta 1690 (2004) 124-133
158. Ritz B., Ascherio A., Checkoway H., Marder K.S., Nelson L.M., Rocca W.A., Ross G.W., Strickland D., Van Den Eeden S.K., and Gorell J. Pooled analysis of tobacco use and risk of Parkinson's disease. Arch. Neurol. 64 (2007) 990-997
159. Roberts R.L., Fine R.E., and Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell Sci. 104 Pt 2 (1993) 521-532
160. Rothenberger S., Food M.R., Gabathuler R., Kennard M.L., Yamada T., Yasuhara O., McGeer P.L., and Jefferies W.A. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res. 712 (1996) 117-121
161. Rouault T.A., Haile D.J., Downey W.E., Philpott C.C., Tang C., Samaniego F., Chin J., Paul I., Orloff D., Harford J.B., et al. An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein. Biometals 5 (1992) 131-140
162. Rouault T.A., Hentze M.W., Caughman S.W., Harford J.B., and Klausner R.D. Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA. Science 241 (1988) 1207-1210
163. Rouault T.A., Tang C.K., Kaptain S., Burgess W.H., Haile D.J., Samaniego F., McBride O.W., Harford J.B., and Klausner R.D. Cloning of the cDNA encoding an RNA regulatory protein-the human iron-responsive element-binding protein. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7958-7962
164. Ryvlin P., Broussolle E., Piollet H., Viallet F., Khalfallah Y., and Chazot G. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch. Neurol. 52 (1995) 583-588
165. Sayre L.M., Moreira P.I., Smith M.A., and Perry G. Metal ions and oxidative protein modification in neurological disease. Ann. Ist. Super Sanita 41 (2005) 143-164
166. Sengstock G.J., Olanow C.W., Dunn A.J., and Arendash G.W. Iron induces degeneration of nigrostriatal neurons. Brain Res. Bull. 28 (1992) 645-649
167. Sengstock G.J., Olanow C.W., Menzies R.A., Dunn A.J., and Arendash G.W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35 (1993) 67-82
168. Shashidharan P., Good P.F., Hsu A., Perl D.P., Brin M.F., and Olanow C.W. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res. 877 (2000) 379-381
169. Shayeghi M., Latunde-Dada G.O., Oakhill J.S., Laftah A.H., Takeuchi K., Halliday N., Khan Y., Warley A., McCann F.E., Hider R.C., Frazer D.M., Anderson G.J., Vulpe C.D., Simpson R.J., and McKie A.T. Identification of an intestinal heme transporter. Cell 122 (2005) 789-801
170. Shi X., Dalal N.S., and Jain A.C. Antioxidant behaviour of caffeine: efficient scavenging of hydroxyl radicals. Food Chem. Toxicol. 29 (1991) 1-6
171. Shima T., Sarna T., Swartz H.M., Stroppolo A., Gerbasi R., and Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 23 (1997) 110-119
172. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N., and Mizuno Y. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45 (1999) 668-672
173. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., and Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74 (1988) 199-205
174. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6469-6473
175. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
176. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., and Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11869-11874
177. Sziraki I., Mohanakumar K.P., Rauhala P., Kim H.G., Yeh K.J., and Chiueh C.C. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 85 (1998) 1101-1111
178. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol. Clin. 14 (1996) 317-335
179. Toku K., Tanaka J., Yano H., Desaki J., Zhang B., Yang L., Ishihara K., Sakanaka M., and Maeda N. Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro. J. Neurosci. Res. 53 (1998) 415-425
180. Uversky V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21 (2003) 211-234
181. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001) 44284-44296
182. Vargas J.D., Herpers B., McKie A.T., Gledhill S., McDonnell J., van den Heuvel M., Davies K.E., and Ponting C.P. Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases. Biochim. Biophys. Acta 1651 (2003) 116-123
183. Viatte L., Lesbordes-Brion J.C., Lou D.Q., Bennoun M., Nicolas G., Kahn A., Canonne-Hergaux F., and Vaulont S. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 105 (2005) 4861-4864
184. Visser C.C., Voorwinden L.H., Crommelin D.J., Danhof M., and de Boer A.G. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm. Res. 21 (2004) 761-769
185. Vokurka M., Krijt J., Sulc K., and Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol. Res. 55 (2006) 667-674
186. Walter U., Wittstock M., Benecke R., and Dressler D. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J. Neural Transm. 109 (2002) 191-196
187. Wang R.H., Li C., Xu X., Zheng Y., Xiao C., Zerfas P., Cooperman S., Eckhaus M., Rouault T., Mishra L., and Deng C.X. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2 (2005) 399-409
188. Wesemann W., Blaschke S., Solbach M., Grote C., Clement H.W., and Riederer P. Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural Transm., Parkison's Dis. Dement. Sect. 8 (1994) 209-214
189. Wijewickreme A.N., and Kitts D.D. Modulation of metal-induced genotoxicity by Maillard reaction products isolated from coffee. Food Chem. Toxicol. 36 (1998) 543-553
190. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., and Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 75 (2004) 637-639
191. Wrighting D.M., and Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 108 (2006) 3204-3209
192. Wu L.J., Leenders A.G., Cooperman S., Meyron-Holtz E., Smith S., Land W., Tsai R.Y., Berger U.V., Sheng Z.H., and Rouault T.A. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res. 1001 (2004) 108-117
193. Xiong S., Markesbery W.R., Shao C., and Lovell M.A. Seleno-l-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death. Antioxid. Redox Signal. 9 (2007) 457-467
194. Yanagimoto K., Ochi H., Lee K.G., and Shibamoto T. Antioxidative activities of fractions obtained from brewed coffee. J. Agric. Food Chem. 52 (2004) 592-596
195. Ye F.Q., Allen P.S., and Martin W.R. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov. Disord. 11 (1996) 243-249
196. Youdim M.B., Ben-Shachar D., and Riederer P. The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm., Suppl. 43 (1994) 113-122
197. Youdim M.B., Stephenson G., and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 1012 (2004) 306-325
198. Zareba M., Bober A., Korytowski W., Zecca L., and Sarna T. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta. 1271 (1995) 343-348
199. Zayed J., Ducic S., Campanella G., Panisset J.C., Andre P., Masson H., and Roy M. Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 17 (1990) 286-291
200. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W.D., Musicco M., Tampellini D., Riederer P., Gerlach M., and Becker G. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov. Disord. 20 (2005) 1278-1285
201. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., and Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 (2001) 1766-1773
202. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2005) 544-549
203. Zijp I.M., Korver O., and Tijburg L.B. Effect of tea and other dietary factors on iron absorption. Crit. Rev. Food Sci. Nutr. 40 (2000) 371-398